{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-21-000016","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2021-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.237731+00:00","generated_at":"2026-06-28T15:19:27.893971+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nautilus Q3 net loss widens to $14.5M; OpEx up 262%; cash at $374M","bullets":["Net loss of $14.5M for Q3 2021 vs. $4.0M loss in Q3 2020.","Operating expenses $14.6M, up 262% YoY on higher headcount and public-company costs.","Cash, cash equivalents and investments totaled $374.0M at September 30, 2021.","Strategic partnership with Abcam and two new research collaborations (pharma and MD Anderson).","Published theoretical foundation for PrISM single-molecule protein identification method."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-21-000016","json":"https://secwatch.observer/filing/0001808805-21-000016.json","markdown":"https://secwatch.observer/filing/0001808805-21-000016.md","text":"https://secwatch.observer/filing/0001808805-21-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880521000016/0001808805-21-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880521000016/naut-20211102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:19:27.893971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}